Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials

Cancer Medicine

Volumn 5, Issue 7, 2016, Pages 1481-1491

  Yun, Seongseok ^a,b   Vincelette, Nicole D ^c   Green, Myke R ^b   Wahner Hendrickson, Andrea E ^d   Abraham, Ivo ^b,e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

CTLA 4; Ipilimumab; Lambrolizumab; metastatic melanoma; nivolumab; PD 1; pembrolizumab; tremelimumab

Indexed keywords

B RAF KINASE; CARBOPLATIN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLYCOPROTEIN GP 100; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TEMOZOLOMIDE; TICILIMUMAB;

ARTICLE; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84991526099     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.732     Document Type: Article

References (67)

1. Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507–2516.
2. Long, G. V., D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, et al. 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371:1877–1888.
3. Long, G. V., U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, et al. 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13:1087–1095.
4. McArthur, G. A., P. B. Chapman, C. Robert, J. Larkin, J. B. Haanen, R. Dummer, et al. 2014. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15:323–332.
5. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736.
6. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–264.
7. Ribas, A., R. Kefford, M. A. Marshall, C. J. Punt, J. B. Haanen, M. Marmol, et al. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:616–622.
8. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793–800.
9. Okazaki, T., S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo. 2013. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14:1212–1218.
10. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107:4275–4280.
11. Topalian, S. L., M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020–1030.
12. Weber, J. S., S. P. D'Angelo, D. Minor, F. S. Hodi, R. Gutzmer, B. Neyns, et al. 2015. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384.
13. Weber, J. S., R. R. Kudchadkar, B. Yu, D. Gallenstein, C. E. Horak, H. D. Inzunza, et al. 2013. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31:4311–4318.
14. Robert, C., A. Ribas, J. D. Wolchok, F. S. Hodi, O. Hamid, R. Kefford, et al. 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117.
15. Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman; Prisma Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62: 1006–1012.
16. Yun, S., N. D. Vincelette, and I. Abraham. 2015. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad. Med. J. 91:627–633.
17. Thompson, J. A., O. Hamid, D. Minor, A. Amin, I. G. Ron, R. Ridolfi, et al. 2012. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J. Immunother. 35:73–77.
18. Ackerman, A., O. Klein, D. F. McDermott, W. Wang, N. Ibrahim, D. P. Lawrence, et al. 2014. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:1695–1701.
19. Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134–144.
20. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443–2454.
21. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122–133.
22. Wolchok, J. D., B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, et al. 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:155–164.
23. Hersh, E. M., S. J. O'Day, J. Powderly, K. D. Khan, A. C. Pavlick, L. D. Cranmer, et al. 2011. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest. New Drugs 29:489–498.
24. Weber, J., J. A. Thompson, O. Hamid, D. Minor, A. Amin, I. Ron, et al. 2009. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15:5591–5598.
25. O'Day, S. J., M. Maio, V. Chiarion-Sileni, T. F. Gajewski, H. Pehamberger, I. N. Bondarenko, et al. 2010. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21:1712–1717.
26. Hodi, F. S., S. Lee, D. F. McDermott, U. N. Rao, L. H. Butterfield, A. A. Tarhini, et al. 2014. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744–1753.
27. Ascierto, P. A., E. Simeone, V. C. Sileni, J. Pigozzo, M. Maio, M. Altomonte, et al. 2014. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J. Transl. Med. 12:116.
28. Chiarion Sileni, V., J. Pigozzo, P. A. Ascierto, A. M. Grimaldi, M. Maio, L. Di Guardo, et al. 2014. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J. Exp. Clin. Cancer Res. 33:30.
29. Di Giacomo, A. M., P. A. Ascierto, L. Pilla, M. Santinami, P. F. Ferrucci, D. Giannarelli, et al. 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13:879–886.
30. Di Giacomo, A. M., P. A. Ascierto, P. Queirolo, L. Pilla, R. Ridolfi, M. Santinami, et al. 2015. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann. Oncol. 26:798–803.
31. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:3167–3175.
32. Weber, J. S., S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, et al. 2008. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26:5950–5956.
33. Maker, A. V., G. Q. Phan, P. Attia, J. C. Yang, R. M. Sherry, S. L. Topalian, et al. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12:1005–1016.
34. Ascierto, P. A., E. Simeone, V. C. Sileni, M. Del Vecchio, P. Marchetti, G. C. Cappellini, et al. 2014. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest. 32:144–149.
35. Eggermont, A. M., V. Chiarion-Sileni, J. J. Grob, R. Dummer, J. D. Wolchok, H. Schmidt, et al. 2015. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530.
36. Maio, M., J. J. Grob, S. Aamdal, I. Bondarenko, C. Robert, L. Thomas, et al. 2015. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 33:1191–1196.
37. McDermott, D., J. Haanen, T. T. Chen, P. Lorigan, S. O'Day, M-. Investigators. et al. 2013. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010–20). Ann. Oncol. 24:2694–2698.
38. Sherrill, B., J. Wang, S. Kotapati, and K. Chin. 2013. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br. J. Cancer 109:8–13.
39. Lebbé, C., J. S. Weber, M. Maio, B. Neyns, K. Harmankaya, O. Hamid, et al. 2014. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann. Oncol. 25:2277–2284.
40. Wolchok, J. D., J. S. Weber, M. Maio, B. Neyns, K. Harmankaya, K. Chin, et al. 2013. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann. Oncol. 24:2174–2180.
41. Prieto, P. A., J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White, et al. 2012. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18:2039–2047.
42. Dummer, R., A. Daud, I. Puzanov, O. Hamid, D. Schadendorf, C. Robert, et al. 2015. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J. Transl. Med. 13:2062.
43. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517–2526.
44. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711–723.
45. Robert, C., G. V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320–330.
46. Ribas, A., I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, et al. 2015. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16:908–918.
47. Balch, C. M., J. E. Gershenwald, S. J. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, et al. 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27:6199–6206.
48. Guyatt, G. H., D. L. Sackett, J. C. Sinclair, R. Hayward, D. J. Cook, and R. J. Cook. 1995. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 274:1800–1804.
49. Burns, P. B., R. J. Rohrich, and K. C. Chung. 2011. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 128:305–310.
50. Robert, C., J. Schachter, G. V. Long, A. Arance, J. J. Grob, L. Mortier, et al. 2015. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med.
51. Larkin, J., V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, C. L. Cowey, C. D. Lao, et al. 2015. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med.
52. NCCN Guideline, Melanoma, Version 2.2016: http://www.nccn.org/.
53. Daud, A., A. Ribas, C. Robert, S. Hodi, J. Wolchok, A. Joshua, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. JCO2015.
54. Taube, J. M., A. Klein, J. R. Brahmer, H. Xu, X. Pan, J. H. Kim, et al. 2014. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20:5064–5074.
55. Postow, M. A., J. Chesney, A. C. Pavlick, C. Robert, K. Grossmann, D. McDermott, et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006–2017.
56. Madore, J., R. E. Vilain, A. M. Menzies, H. Kakavand, J. S. Wilmott, J. Hyman, et al. 2015. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28:245–253.
57. Tumeh, P. C., C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor, L. Robert, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571.
58. Rizvi, N. A., M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124–128.
59. Kluger, H., M. Sznol, M. Callahan, M. A. Postow, R. A. Gordon, N. H. Segal, et al. 2014. Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). Ann Oncol.
60. Sznol, M., H. M. Kluger, M. K. Callahan, M. A. Postow, R. A. Gordon, N. H. Segal, et al. 2014. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol.
61. Larkin, J., C. D. Lao, W. J. Urba, D. F. McDermott, C. Horak, J. Jiang, et al. 2015. Efficacy and safety of nivolumab in patients With BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 1:433–440.
62. Robert, L., J. Tsoi, X. Wang, R. Emerson, B. Homet, T. Chodon, et al. 2014. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20:2424–2432.
63. Das, R., R. Verma, M. Sznol, C. S. Boddupalli, S. N. Gettinger, H. Kluger, et al. 2015. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194:950–959.
64. Hoos, A., J. D. Wolchok, R. W. Humphrey, and F. S. Hodi. 2015. CCR 20th anniversary commentary: immune-related response criteria-capturing clinical activity in immuno-oncology. Clin. Cancer Res. 21:4989–4991.
65. Wolchok, J. D., A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbé, et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:7412–7420.
66. Fellner, C. 2012. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P. T. 37:503–530.
67. Yun, S., N. D. Vincelette, I. Mansour, D. Hariri, and S. Motamed. 2015. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep. Oncol. Med. 2015:794842.